Bard Financial Services Inc. Decreases Holdings in Novo Nordisk A/S $NVO

Bard Financial Services Inc. reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 13.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 60,275 shares of the company’s stock after selling 9,695 shares during the quarter. Bard Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $3,345,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. NewSquare Capital LLC lifted its position in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new stake in Novo Nordisk A/S during the second quarter valued at about $37,000. State of Wyoming purchased a new stake in Novo Nordisk A/S during the first quarter valued at about $38,000. Maseco LLP bought a new position in Novo Nordisk A/S during the second quarter worth about $39,000. Finally, Copeland Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 47.3% in the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after purchasing an additional 186 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.5%

Shares of Novo Nordisk A/S stock opened at $52.29 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The firm has a market cap of $233.49 billion, a PE ratio of 15.20 and a beta of 0.67. The company has a 50 day simple moving average of $49.35 and a two-hundred day simple moving average of $56.77.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 22nd. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. Hsbc Global Res cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Finally, HSBC reissued a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.